amivantamab + hyaluronidase + lazertinib

Rybrevant Faspro + lazertinib is a combination regimen consisting of Rybrevant Faspro (a subcutaneous co-formulation of amivantamab, an EGFR-MET bispecific antibody, and recombinant human hyaluronidase PH20) and lazertinib (Lazcluze), an oral third-generation EGFR tyrosine kinase inhibitor (TKI). Developed by Johnson & Johnson (Janssen Biotech) in collaboration with Yuhan Corporation, this combination is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations. Amivantamab binds to the extracellular domains of EGFR and MET, blocking ligand binding and promoting receptor degradation and immune-mediated tumor clearance, while lazertinib acts intracellularly to selectively and irreversibly inhibit mutant EGFR kinase activity. The inclusion of hyaluronidase in Rybrevant Faspro enables rapid subcutaneous administration (approximately 5 minutes) compared to the multi-hour intravenous infusion of standard amivantamab, significantly reducing administration-related reactions and improving patient convenience.